Desmosterol in Brain Is Elevated because *DHCR24* Needs *REST* for Robust Expression but *REST* Is Poorly Expressed

G.S. Tint^{a, b} Luxing Pan^a Quan Shang^{a, b} Laura J. Sharpe^e Andrew J. Brown^e
Man Li^f Hongwei Yu^{c, d}

^aResearch Service, Department of Veterans Affairs Medical Center, East Orange, N.J., ^bDepartment of Medicine, Rutgers New Jersey Medical School, Newark, N.J., ^cMedical College of Wisconsin, and ^dClement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisc., USA; ^eSchool of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, N.S.W., Australia; ^fQilu Hospital, Shandong University, Jinan, PR China

Key Words

Cholesterol · Regulation · Neural tissue · Development · Repressor element 1 sequence · Sterol response element

Abstract

Cholesterol synthesis in the fetal brain is inhibited because activity of *DHCR24* (24-dehydrocholesterol reductase) is insufficient, causing concentrations of the precursor desmosterol to increase temporarily to 15–25% of total sterols at birth. We demonstrate that failure of *DHCR24* to be adequately upregulated during periods of elevated cholesterol synthesis in the brain results from the presence in its promoter of the repressor element 1 (RE1) nucleotide sequence that binds the RE1-silencing transcription factor (*REST*) and that *REST*, generally reduced in neural tissues, uncharacteristically but not without precedent, enhances *DHCR24* transcription. *DHCR24* and *REST* mRNA levels are reduced 3- to 4-fold in fetal mouse brain compared to liver ($p < 0.001$). Chromatin immunoprecipitation assays suggested that *REST* binds to the human *DHCR24* promoter in the vicinity of the predicted human RE1 sequence. Luminescent emission from a human *DHCR24* promoter construct with a mutated RE1 sequence was reduced 2-fold compared to output

from a reporter with wild-type RE1 ($p < 0.005$). Silencing *REST* in HeLa cells resulted in significant reductions of *DHCR24* mRNA (2-fold) and *DHCR24* protein (4-fold). As expected, relative concentrations of Δ^{24} -cholesterol precursor sterols increased 3- to 4-fold, reflecting the inhibition of *DHCR24* enzyme activity. In contrast, mRNA levels of *DHCR7* (sterol 7-dehydrocholesterol reductase), a gene essential for cholesterol synthesis lacking an RE1 sequence, and concentrations of *HMGR* (3-hydroxy-3-methyl-glutaryl-CoA reductase) enzyme protein were both unaffected. Surprisingly, a dominant negative fragment of *REST* consisting of just the DNA binding domain (about 20% of the protein) and full-length *REST* enhanced *DHCR24* expression equally well. Furthermore, RE1 and the sterol response element (SRE), the respective binding sites for *REST* and the SRE binding protein (SREBP), are contiguous. These observations led us to hypothesize that *REST* acts because it is bound in close proximity to SREBP, thus amplifying its ability to upregulate *DHCR24*. It is likely that modulation of *DHCR24* expression by *REST* persisted in the mammalian genome either because it does no harm or because suppressing metabolically active *DHCR24* while providing abundant quantities of the multifunctional sterol desmosterol during neural development proved useful.

© 2014 S. Karger AG, Basel

Introduction

Regulation of cholesterol metabolism in the fetal mammalian brain is puzzling because, at a time when the entire cholesterol biosynthetic pathway is massively upregulated, the reaction that reduces the sterol C24,25-double bond (online suppl. fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000362363), catalyzed by DHCR24 (24-dehydrocholesterol reductase), fails to keep pace.

Although the mature brain is our most cholesterol-rich organ [1], an efficient block forms early in gestation, preventing the mother from supplying more than about 25% of the cholesterol needed by her newborn fetus [2–4]. Despite the nearly complete bar to maternal cholesterol transfer imposed by the blood-brain barrier, which forces the fetal brain to make most of its own cholesterol [4], activity of DHCR24 is inadequate [4, 5]. As a result, desmosterol, as the ultimate cholesterol precursor, accumulates to 15–25% of total brain sterols at birth [4, 6–8]. This unusually large pool of desmosterol does not persist, however, because an older brain (as well as peripheral nerves) makes very little new cholesterol, much preferring to recycle [9, 10]. This enables most desmosterol to be converted to cholesterol, albeit somewhat slowly [5, 8, 11].

DHCR24, unique among the genes of cholesterol synthesis and metabolism in its failure to be expressed adequately, is an FAD-dependent oxidoreductase [12] thought capable of reducing the C24,25-double bond of most Δ^{24} -cholesterol intermediates, including desmosterol during cholesterol biosynthesis [13, 14] (online suppl. fig. 1). Here we demonstrate that expression of DHCR24 at levels sufficient to accommodate the high rates of cholesterol synthesis in the developing brain requires the presence of repressor element 1 (RE1)-silencing transcription factor (REST)/neuron-restrictive silencing factor, a Krüppel-like zinc finger protein whose expression is normally suppressed in neural tissues [15–18]. Most often REST, after recruiting corepressors and cofactors, initiates the essential process of transcriptionally silencing neuronal genes in nonneuronal cells. However, on rare occasions, and for a variety of reasons, REST can also function in the opposite role of enhancer [19–22] which, as we demonstrate, it does for DHCR24.

It is important to note that DHCR24 activity in the fetal brain is sufficient to reduce the Δ^{24} -double bonds of 70–75% of the cholesterol precursor molecules that the average fetal mouse brain needs to synthesize before birth [4]. As a consequence, a large order of magnitude changes in DHCR24 ought not to be expected.

Several hundred-fold elevations of desmosterol and 2- to 4-fold reductions of DHCR24 are not likely to be without consequence to the fetal and embryonic brain. As will be discussed in detail below, both molecules are bioactive and are capable of altering sterol and triglyceride synthesis and transport, lipid raft formation, neural cell stability, etc. [14] – processes known to be essential for proper brain development. Therefore, it may be that reduced activity of DHCR24 has become essential for the complex mammalian brain and is now intentional and closely regulated.

Materials and Methods

Reagents

Dulbecco's MEM/F12 and BSA IV were obtained from Invitrogen (Grand Island, N.Y., USA) while lipoprotein-deficient bovine calf serum containing <25 µg/ml of cholesterol was purchased from Biomedical Technologies (Stoughton, Mass., USA). Sterols were purchased from Sigma-Aldrich (St. Louis, Mo., USA) or Steraloids (Newport, R.I., USA) and reagents for processing sterols for gas chromatography (GC) were obtained from Sigma-Aldrich or Fisher Scientific.

Animals

C57BL/6J mice were fed a commercial chow diet, bred and a successful mating identified by a vaginal plug. Pregnant mice were sacrificed following accepted humane protocols and fetal tissues were harvested and placed in RNAlater (Ambion, Austin, Tex., USA) or else frozen in liquid nitrogen and then stored at –70°C for future sterol analysis [4, 23]. All animal experiments complied with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and were performed with the approval of the Institutional Animal Care and Use Committee, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisc., USA.

Quantitative RT-PCR

Quantitative RT-PCR (qRT-PCR) was carried out with TaqMan® Genomic Assay kits designed by Applied Biosystems (Foster City, Calif., USA) for the appropriate genes as described previously [4]. The results as shown employed cyclophilin as the endogenous control. When we compared expression in the brain and liver, measurements were repeated with β -actin and GAPDH, which yielded similar results.

Chromatin Immunoprecipitation Assay

The chromatin immunoprecipitation (ChIP) assay was carried out in HeLa cells grown in DMEM plus FBS using the EZ ChIP Chromatin Immunoprecipitation Kit (Upstate/Millipore, Billerica, Mass., USA) according to the manufacturer's instructions. REST bound to chromatin was immunoprecipitated with antibody supplied by Upstate. After reverse cross-linking, the precipitated DNA was purified and quantified by PCR using primers 5'-AGT ATT CGC AGC GGA CCC CAC and 3'-GGT TCG CGC CTC CTG TCA CT, F and R, respectively, covering a 292-nucleotide region spanning the putative REST binding sites. Positive controls were provided by the input sample, by precipitation with antibody

to polymerase II followed by amplification with primers F and R, and by precipitation with REST antibody followed by PCR with primers 5'-TGC ATT GCT GAT GCT GCT GCT and 3'-TGG CCA CCA CCT CCC AGA GTC (137 bp) for *Synapsin 1* (*SYN1*) [24]. Negative controls included precipitation by mouse IgG, amplification of the human *GAPDH* promoter with the primer pair 5'-TAC TAG CGG TTT TAC GGG CG, 3'-TCG AAC ACG AGG AGC AGA GAG CGA (165 bp) after precipitation with REST antibody and, after precipitation with REST antibody, with primers 5'-AGG CAG CTG GAG AAG TTT GT and 3'-CTT GCA GAT CTT GTC GTA CA that amplified a 1,221-bp segment (3'-DHCR24) spanning the final *DHCR24* intron/exon boundary excluding nonspecific REST binding to *DHCR24*. The sizes of the PCR products were confirmed by comparing their mobilities with those of molecular weight standards.

Luciferase Assay

The gene encoding human REST, CloneID: 40146881, obtained from Open Biosystems (now Fisher Scientific) was subcloned into pcDNA4/mycHisB (Life Technologies). A dominant negative fragment of REST (DN-REST), containing only the REST DNA binding domain, aa 234–437 (about 20% of the native protein [18]), was also subcloned into the same vector.

The Renilla luciferase construct used in these studies driven by the porphobilinogen deaminase promoter (phRL-PBGD) and the Firefly luciferase construct driven by 300 bp of the human *DHCR24* promoter (pGL3-basic/300luc) have been described previously [25]. The predicted RE1 binding site RE1_b was mutated (RE1mut) in pGL3-basic/300luc using megaprimered PCR [26].

HeLa T cells were grown in triplicate in 24-well plates and transfected with 250 ng of Firefly luciferase plasmid, 25 ng phRL-PBGD and 25 ng pcDNA4/REST or pcDNA4/DN-REST plasmid, using TransIT-2020 (Mirus Bio, Madison, Wisc., USA) for 24 h. Cells were then lysed and assayed for Firefly and Renilla luciferase activities using the Dual Luciferase Reporter Assay System (Promega, Fitchburg, Wisc., USA). Relative luciferase activity was calculated as the ratio of Firefly to Renilla activity for each sample.

Transient REST Silencing

Eighty percent confluent HeLa cells in 8-well plates were incubated with a pool containing the four REST silencing double-stranded 21-nucleotide RNAs designed and supplied by Dharmacon (Pittsburgh, Pa., USA): CAA CGA AUC UAC CCA UAU UUU; GGU GAA ACU UUA AAU GGU AUU; UGA CUU GCC UGA UAA UAU UUU, and CAU CCU ACU UGU CCU AAU AUU together with DHARMAdfect transfection reagent according to the manufacturer's protocol. After 4 h the transfection reagent was replaced by normal culture medium (DMEM plus 20% FBS) and the cells were allowed to grow for an additional 44 h. Following reverse transcription the relative concentrations of *REST*, *DHCR24* and *DHCR7* mRNA were measured by qRT-PCR as described previously [4]. Controls were provided by cells incubated with a random double-stranded RNA: UAA GGC UAU GAA GAG AUA C.

Stable REST Silencing

HeLa cells were cultured in DMEM containing 10% FBS plus 100 U/ml penicillin and 100 µg/ml streptomycin. One day before transfection, the cells were seeded in 6-well cell culture plates to a final density of 60–70%. Lentiviral shRNA vectors (pGIPZ) containing the human *REST* hairpin targeting sequence TGC TGT

TGA CAG TGA GCG CGC GGC TAC AAT ACT AAT CGA TTA GTG AAG CCA CAG ATG TAA TCG ATT AGT ATT GTA GCC GCA TGC CTA CTG CCT CGG A or a nonsilencing control sequence (Open Biosystems, Pittsburgh, Pa., USA) were transfected into the cells with Arrest-In transfection reagent according to the manufacturer's protocol. After 48 h, the cells were cultured in 5 µg/ml puromycin-containing media to select pGIPZ vector-expressing cells. Gradually increasing the concentration of puromycin to 30 µg/ml, after about 3–4 weeks of culture vector-encoded independent green fluorescent protein expression was observed in all cells and confirmed by fluorescent-activated cell sorting. REST expression in the plasmid-transfected cells was characterized by real-time qPCR and immunoblotting. For sterol measurements, cells stably transfected with the plasmid containing silencing or nonsilencing (control) sequences were cultured in DMEM/F12 supplemented with 1% lipoprotein-deficient bovine calf serum and 0.5% BSA for 6–10 days (medium changed every day) and then extracted and analyzed as described below.

Sterol Measurements

Sterols, were extracted, hydrolyzed and measured as the trimethylsilyl ether derivatives by capillary column GC (tissues) and GC/MS selected ion monitoring (cultured cells) as described previously [4]. For selected ion monitoring m/z was set to 393 (lanosterol), 395 (24,25-dihydrolanosterol), 343 (desmosterol) and 329 (cholesterol).

Immunoblotting

Rabbit anti-REST and anti-HMGR (3-hydroxy-3-methylglutaryl-CoA reductase) antibodies were obtained from Millipore (Billerica, Mass., USA), rabbit anti-DHCR24 antibody against an N-terminal peptide corresponding to amino acids 68–85 of the human *DHCR24* protein was supplied by Sigma-Aldrich, and a mouse monoclonal anti-GAPDH antibody by Abcam (Cambridge, Mass., USA). Whole cell lysates and nuclear proteins were prepared from approximately 10⁷ cultured cells using an NE-PER kit (Pierce, Waltham, Mass., USA) and protein concentrations were determined using a BCA protein assay kit (Fisher Scientific); 40-µg protein aliquots from each sample were separated on SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk and incubated with a REST (1:500), a *DHCR24* (1:4,000) and a GAPDH antibody (1:10,000) followed by incubation with HRP-conjugated second antibodies. Specific interactions were revealed using the enhanced chemiluminescence detection system (Amersham, Pittsburgh, Pa., USA). Densitometric quantification of the immunoblot bands from controls (empty vector, EV) or REST knock-down samples were quantified using NIH image 1.63 software.

Statistical Analysis

Most results are presented as the mean ± 95% confidence interval (95% CI) with differences between groups analyzed by the two-tailed t test. Ratios of luminescent outputs obtained from reporter constructs containing a mutated RE1 sequence (RE1mut) divided by the output from wild-type RE1 reporters and ratios of C24,25 unsaturated-to-saturated sterols were employed to calculate differences by the two-tailed single-sample t test with the null hypothesis that the mean = 1, i.e. that results before and after mutating RE1 or sterol ratios before and after silencing REST are equal (GraphPad; Systat, Chicago, Ill., USA).

Fig. 1. *Rest* and *Dhcr24* expression are markedly reduced in the mouse brain compared to the liver. qRT-PCR analysis of *Dhcr24* and *Rest* from fetal and newborn mouse brain and liver demonstrating reduced expression of both in the brain; mean $\pm$ 95% CI. * $p < 0.001$ brain vs. liver ($n = 12$, two-tailed t test). These results employed β -actin as the endogenous control but cyclophilin and GAPDH yielded very similar results (data not shown), confirming that the differences between the brain and liver are real. **Insert** Desmosterol as percent of total sterols vs. age, illustrating markedly elevated desmosterol levels in fetal brain (black bars) compared to liver (white bars) at E14.5 and at birth (P0); mean $\pm$ SD. * $p < 0.005$ brain vs. liver ($n = 3$, two-tailed t test).

Results

qRT-PCR confirmed that mRNA levels of both *Rest* and *Dhcr24* are reduced 3- to 4-fold ($p < 0.005$) in fetal and newborn mouse brain compared to liver (fig. 1). Figure 1 also includes a plot demonstrating massively increased desmosterol concentrations in the brain compared to the liver.

A detailed analysis by MatInspector [27] of 2,500 bp of the predicted, and recently confirmed [25, 28, 29], mouse and human *DHCR24* promoters, well conserved across the vertebrate genome, suggested potential binding sequences for REST, with three in the mouse,

RE1_{a-c}, and one, RE1_b, in the human gene (fig. 2). The mammalian RE1_b sequence, in particular, is very similar to the sequence observed in the chicken. These sites, all within 260 bp of the putative translation start site pointed to *REST*, a gene poorly expressed in neural tissues, as a possible modulator of *DHCR24* transcription. However, since expression and activity of *DHCR24* are inhibited in the brain (fig. 1), *REST* would not be acting here in its usual role of suppressor but instead is functioning in its more uncommon one of transcriptional enhancer. We focused our investigation here on the human gene.

ChIP assays (fig. 3) demonstrated that REST binds to the human *DHCR24* promoter within the 292-nucleotide region containing the predicted REST sequences. Positive controls polymerase II and *SYN1* elicited strong signals for REST while there was little or no response from negative controls including the amplification of a large segment of the final *DHCR24* intron/exon boundary.

To confirm that it is the RE1_b site (fig. 2) in the human promoter that is essential for upregulating *DHCR24* by REST, we carried out a series of studies employing a luciferase reporter system [25] constructed from either the wild-type *DHCR24* promoter (RE1) or the identical promoter with the RE1_b binding sequence mutated (RE1mut) as shown in figure 4a. As described above, in an effort to reduce scatter we express the results as luminescence ratios (fig. 4b). But, in figure 4c we also present these data in their familiar normalized form so that the effects of mutating RE1 are more visually obvious. Relative luciferase outputs (RE1mut:RE1) obtained after incubating with either full-length REST or DN-REST, a dominant negative REST fragment consisting of just the DNA binding region (about 20% of the native protein) were reduced by as much as 50% ($p < 0.005$) and demonstrate that mutating RE1_b indeed suppresses *DHCR24* expression (fig. 4b, c). Mutating RE1_b also tended to diminish the luminescence output of the RE1mut reporter compared to the output from the reporter constructed from wild-type RE1 ($p = 0.065$; fig. 4b) after both were cotransfected with an EV rather than with REST or DN-REST. This result suggests that, in the absence of other unrecognized cofactors or subtle experimental errors in the synthesis of the two reporters, it is likely that the pre-existing, endogenous cellular pool of REST, without being supplemented with exogenous protein, is of sufficient size and activity to amplify the expression of transfected luciferase *DHCR24* promoter constructs sufficiently to uncover differences between the RE1 and RE1mut reporters.

F

Hs: GAAGAGGCGGCCCCGAGCC-CCGAGGGCTGGGG--CCCTGAGTCCCAACTGCC---ACCCCCAGTA 317
Mm: --AAGGGTGGTCCCGCTGCCTCCA-GAGCGAGAG--CCCTAAACCCCGCCAAGCC---CGCCGC--TT 315
Gg: -----GTACCTCAGTC-CCCAGGGGATGGA--CCCCAGCCC-TTCAGCCCA---CACGGGAAT 329

.....

Hs: TTC--GCAGCGGACC--CCA--CCGGC--ACCCAGTC--CCTG-GCA-CCCCGCCTCG--CGCGGCGGC 261
Mm: GCC--GACCC--TAC--CAG--CG--C--CCCCAGCC--CAGG-TCA-GCCCCTCCTCG--CACGCCGAC 263
Gg: CCGCGCCCCCAGCC--CCATCCCCGC--CCCCCGTC--CAGGTGCTGCCCCGCCCAACCCGCGCGC 265

RE1_a **RE1_b**

Hs: GG-GGAGAAAAGGTGGAGCGGT-CCGACTCC--CGCAGCCAATGAAAGCTG-CGGGTTCCTG**GTTCCGAT** 196
Mm: TA-GAAGA---GGGT**GAGCATC-CCGGTTCC--CGCAGCCAATGAACGCAG-CGGCTCCCTG**GTTCCGAT**** 201
Gg: CGCGATGAGGGG---AGAGCGGGGCCGGC-CCGGCGCAGCCAATCAGCGCCGTCAGCG-CCTGGTCCGAT 200

Hs: **C-CCCGGCGCGGCTCGCC**-ATTGGTCGCGCGCCGGGTCTCGGCCACCGAACCTCGGCGACCCGAG-CCA 129
Mm: **C-CCCGGCGCGGCTCAAC**-ATTGGTCGCGCGCTGGGTCTCGGCCACCGAACCTTGCGGACCCAAG-CCA 134
Gg: CTCCC--CGCAGCTCTCTGATTGGTCGCTCCCTCCCCTCG--CCTCAGGGCGGAGGCCGGCGGAGACCA 134

RE1_c

Hs: ATCGCGAGGCGGCGGGC---GATCCCGGGCTCCCCGGGC--TGTGGGCTACAGGCGCAGAGCGGGCCAGG 64
Mm: ATCGCGAGGCGGCGGGCCCGACTTACAGGCTCCCGGGGC--GGTGGCG-GCAGGCGCTGAGC**CGGCGGAG** 67
Gg: AT---GAGACGCCGG-CTCAGGG--GGGAGGCGGGGCCGGGAGGCGAGC--GCGC-GAGC-GGC-GGG 75

..... **R**

Hs: CGCGGAGC---TGG---CGGCAGTGACAG-GAGGCGCGAACCCGAGCGCTTACCGC--GCGG--CGCC 6
Mm: **CGCGGAGC**---GGG---CGAAGGAGACGG-GCGGCGGAGCCCGCACCTT--CCGC--GCGGTGCGCC 9
Gg: CGCGGTGCACCGGGGTCCGGCGGTG-CGGTGCGGTGCGGTACCG-TGCGGT-GCGGT--GCGGTGCGGT 10

Hs: GC---ACCATG -3
Mm: GCG-ACACCATG -3
Gg: GCGGTGCCCATG -3

▲

Fig. 2. The putative *DHCR24* promoter is well conserved in the chicken, mouse and human genomes. Gg = Chicken; Mm = mouse; Hs = human. The sequences in bold type represent the three REST/NRSF binding sites in the mouse (RE1_a, RE1_b and RE1_c) and the one in the human (RE1_b) gene predicted by MatInspector. F and R and the dashed lines indicate the sequences of the respective for-

ward and reverse primers used to amplify the region bracketing the three suspected REST binding domains for the CHIP assay. The vertical arrowhead marks the likely translation start site. In particular, the RE1_b sequence, although not suggested by MatInspector as a REST/NRSF binding sequence in the chicken, is remarkably similar to both mouse and human.

It is also important to note that *DHCR24* expression was enhanced at least as well by DN-REST as it was by REST and that total photon emission tends to be increased when the former is substituted for the latter (fig. 4d).

If we are correct about the effect of REST on *DHCR24*, then silencing *REST* in any cell line in which *DHCR24* is well expressed should suppress *DHCR24* mRNA, protein levels and enzyme activity, the latter being measured by quantifying increases in the concentrations of common C24,25-unsaturated sterols. A brief 4-hour treatment of HeLa cells with *REST* siRNA followed by a further 2 days of growth in normal medium led to a

10-fold suppression of *REST* and a highly significant 2-fold inhibition of *DHCR24* mRNA (fig. 5a). In contrast, expression of *DHCR7* (7-dehydrocholesterol Δ^7 -reductase), another enzyme essential for cholesterol biosynthesis, robustly active in all tissues including brain [11] but without identifiable RE1 sequences, remained unchanged. In a complementary experiment, HeLa cells were treated for 6–10 days with a stable REST hairpin silencing vector. As a result, levels of *DHCR24* and REST protein declined 4- and 5-fold, respectively, ($p < 0.0025$; fig. 5b) but, as expected, HMGR protein was unchanged. Concentrations of two of the most abundant Δ^{24} -unsaturated sterols, lanosterol and desmoster-

ol (fig. 5c) experienced respective 3- and 4-fold increases relative to their C24,25-saturated products ($p = 0.028$ and $p = 0.068$, respectively), reflecting the expected decrease in DHCR24 protein enzyme activity when *REST* is suppressed.

Discussion

The observation that markedly increased concentrations of cholesterol precursors are engendered by diseases of abnormal cholesterol biosynthesis is well understood [30–32]. But, the massive, somewhat transient, accumulation of desmosterol in the healthy fetal mammalian brain [4, 6, 7] has always been confounding.

DHCR24 appears to be unique among the genes of cholesterol biosynthesis in that it is the only one that is always ‘inadequately’ upregulated in neural tissues. Here we demonstrate that the zinc finger protein, REST, which is expressed poorly in the brain and other neural tissues (fig. 1) and which binds strongly to the *DHCR24* promoter at the RE1_b sequence (fig. 2, 3), is needed to fully upregulate gene expression and yield enzymes abundant enough to permit all newly synthesized desmosterol to be promptly reduced to cholesterol in the fetal brain. We proved that REST is essential because mutating RE1_b (fig. 4a) significantly reduced the output of a *DHCR24* promoter-driven luciferase reporter (fig. 4b), and silencing *REST* (fig. 5) in cultured cells suppressed DHCR24 expression, protein levels and enzyme activity – the last signaled by increased concentrations of the C24,25-unsaturated cholesterol precursors desmosterol and lanosterol. In contrast, other enzyme proteins essential for cholesterol biosynthesis such as DHCR7, a sterol reductase lacking RE1 motifs that functions late in the pathway, and HMGR, an early pathway enzyme usually considered rate limiting, were unaffected.

Generally, it is neural-specific genes that contain RE1 REST binding sequences but *REST* is poorly expressed in the brain and peripheral nerves. This means that only nonneural tissues are likely to have sufficient REST protein to bind to these genes and assemble an activity complex capable of altering histone methylation and acetylation that leads to transcriptional suppression [33–36]. However, in rare instances REST can do the opposite and enhance gene expression, though with little commonality of mechanism or action [19–22]. Our observation that cotransfecting *DHCR24* reporter constructs with DN-REST tended to increase luminescence

Fig. 3. ChIP assay in cultured HeLa cells demonstrates that REST binds to the *DHCR24* promoter in the vicinity of the predicted RE1 binding sequences. Poly II = Polymerase II. PCR products following precipitation by antibodies for polymerase II, REST and IgG are shown together with molecular weight standards on the extreme left: *DHCR24* amplified by the primers F and R shown in figure 2 and positive control *SYN1*, a neural specific gene known to bind REST [24]. GAPDH and amplification with primers for a 1,200-bp fragment spanning the final intron/exon boundary of *DHCR24* (3'-*DHCR24*) provide negative controls. Input is the total sample before treatment.

output compared to cotransfection with full-length REST (fig. 4b–d) suggests that upregulation of *DHCR24* by REST (UniProt Q13127) requires, at most, about 20% of the protein. DN-REST consists of six of the eight REST zinc fingers and little else except linkers. It thus seems highly unlikely that DN-REST could elicit an epigenetic response when it interacts with RE1 because this protein fragment consists of only the REST DNA-binding domain and lacks sequences able to recruit and bind the cofactors necessary to form a REST-like transcriptional suppression complex. It then follows that, unless DN-REST and REST accelerate *DHCR24* expression by different mechanisms, REST does not upregulate *DHCR24* by inhibiting the transcription of some, as yet, unknown *DHCR24* repressor. Taken together, these results suggest that REST is most likely acting locally, pos-

Fig. 4. Luciferase reporter studies demonstrate that REST must bind to the RE1_b site (fig. 2) before full *DHCR24* expression is achieved. **a** Human RE1 consensus [24] together with wild-type *DHCR24* (RE1) and mutated (RE1mut) RE1 sequences; mutated bases are indicated by asterisks; the underlined nucleotides mark -196 InvSRE, one of the functional SREs recently identified by Zerenturk et al. [25]. **b** Relative outputs from luciferase reporter constructs with mutated RE1 depicted in **a** divided by outputs from reporters with wild-type RE1 confirm that mutating RE1_b suppresses *DHCR24* expression (all results given as mean $\pm$ 95% CI). In these studies the reporter constructs were cotransfected with a control EV or with vectors containing either wild-type REST or DN-REST. Mutating the RE1 sequence (RE1mut) significantly reduced luciferase output to $70 \pm 15\%$ ($n = 8$) and $53 \pm 11\%$ ($n = 4$) after cotransfection with vectors containing REST and DN-REST, respectively. Mutating RE1 also tended to reduce luminescence from these same promoters to $90 \pm 10\%$ ($n = 3$) of their original value when cotransfected with an EV when only endogenous REST was available to upregulate *DHCR24*; one-sample t test with mean = 1. * $p = 0.065$, ** $p < 0.005$ that RE1mut and wild-type RE1 luminescence are equal (93.5 and 99.5% probability, respectively, that they are different). **c** The same luminescence data shown normalized to the output from the wild-type RE1 promoter (RE1) after cotransfection with full-length REST. Differences between luminescence from wild-type and mutated promoters cotransfected with REST or DN-REST retain their statistical significance but the more subtle changes in the EV results are now submerged in experimental noise. ** $p < 0.005$. **d** The fragmentary polypeptide DN-REST tends to upregulate *DHCR24* expression more than does full-length REST. Luminescence outputs from wild-type luciferase constructs after incubating with REST (0.088 ± 0.030 , $n = 8$) or DN-REST (0.12 ± 0.071 , $n = 4$). $p = \text{n.s.}$, REST vs. DN-REST.

Fig. 5. Silencing *REST* in HeLa cells inhibits expression, protein and activity of *DHCR24* but does not alter *DHCR7* mRNA or HMGR protein levels. All data presented as mean $\pm$ 95% CI. **a** qRT-PCR of *REST*, *DHCR24* and a differently structured but essential sterol reductase, *DHCR7*, that appears to lack RE1 sequences. HeLa cells were transfected for 4 h with pooled *REST* siRNA, then washed, grown in normal medium and harvested 2 days later (black bars). Controls (white bars, $n = 12$) are cells transfected with random RNA. *REST* expression is reduced 10-fold and *DHCR24* expression 2-fold but *DHCR7* transcription remains unchanged. * $p < 0.001$, ** $p < 0.025$ pre- vs. postsilencing ($n = 18$, two-tailed t test). **b** Relative *REST*, *DHCR24* and HMGR protein levels (normalized to mean GAPDH) from cells incubated for 6 days with a stable lentivirus construct containing a *REST* targeting vector, shRNA or an EV. * $p < 0.0025$ (two-tailed t test, $n = 6$). HMGR protein is unchanged. **c** Ratios of two of the most abundant Δ^{24} -sterol precursors to their respective C24,25-saturated products after a 6-day incubation in lipoprotein-deficient medium in cells treated with vectors containing *REST*-silencing shRNA or an EV (lanosterol:24,25-dihydrolanosterol = 1.08 ± 0.23 vs. 3.36 ± 1.83 , and desmosterol:cholesterol = 0.0055 ± 0.0029 vs. 0.022 ± 0.016 , all $n = 9$). * $p = 0.068$, ** $p = 0.028$ (two-tailed t test).

sibly stimulating *DHCR24* expression by stabilizing and enhancing sterol response element (SRE) binding protein (SREBP) function when both join in tandem to their respective, neighboring nucleotide binding sequences (fig. 4a). Admittedly, this is somewhat specula-

tive and other scenarios are certainly possible. We also cannot rule out a contribution from posttranslational inhibition of *DHCR24* activity in the brain by steroid hormones [8], a hypothesis well beyond the scope of the present study.

Furthermore, because DN-REST tends to be more efficient at activating *DHCR24* expression than does REST (fig. 4), is it possible that REST is also functioning as a somewhat weak transcriptional inhibitor of *DHCR24*, providing for an additional level of regulation?

Because the reduced level of REST found in the fetal brain leads to only partial *DHCR24* inactivation, meaning that there is still sufficient enzyme activity to reduce 75–80% of the desmosterol in the brain to cholesterol before the animal is born [4], we do not suggest that REST is the principle regulator of *DHCR24* activity. Although 2- to 3-fold changes in *DHCR24* expression, similar to those we have measured following REST suppression (fig. 4, 5), have also been reported in cultured cells following treatment with common inhibitors or promoters of cholesterol biosynthesis [25, 29], *Dhcr24* activity in rat liver can be upregulated by as much as 120-fold in response to cholesterol deprivation [13]. Furthermore, recent studies of the *DHCR24* promoter have demonstrated at least two functional SREs as well as the expected regulation of *DHCR24* expression by sterols [25]. This means that primary regulation of *DHCR24* expression, like most if not all genes involved in cholesterol synthesis and transport, appears to require binding of the active SREBP cleavage fragment to SRE [37]. Our current study, in contrast, demonstrates that because REST is essential for the full realization of *DHCR24* expression, it serves as a secondary modulator or cofactor, having its greatest effect in neural tissues in which REST expression is naturally reduced and then only when cholesterol synthesis is substantially elevated as it is in the brain of an embryo or fetus.

Nothing in our data, however, suggests that REST could not also serve as a cofactor for any or all genes regulated by SREBP. However, its absence impacts only *DHCR24*.

Similarly elevated desmosterol concentrations have also long been noted in the gonads [38] in which, at least in the mouse, REST appears to be well expressed [39]. Reduced *DHCR24* activity in these tissues is generally thought to be caused by the naturally abundant progestins [40].

Despite being secondary and indirect, the effects of REST on lipid metabolism are not inconsequential when the cholesterol biosynthetic pathway is as active as it is in the fetal brain. Although inactivating mutations of *DHCR24* in humans lead to a rare, severe and often fatal birth defect [12, 41] and one can build, at best, a viable but poorly functioning mouse from inter-

nally synthesized desmosterol and maternally supplied cholesterol [42], desmosterol itself under normal physiological conditions has a number of nontrivial metabolic effects including an ability to reduce the formation of ordered lipid domains and perhaps impair raft-dependent signaling [43]. Desmosterol has also been reported to be a potent agonist for the liver X receptor and to inhibit cholesterol biosynthesis by blocking SREBP cleavage [44, 45]. Furthermore, *DHCR24*, in common with a number of other proteins associated with cholesterol metabolism, is multifunctional (recently reviewed by Zerenturk et al. [14]) in that it appears to protect neuronal cells from degeneration [46, 47], to modulate levels of the tumor suppressor p53 by binding to its amino terminus enhancing survival of cells during oxidative stress [48, 49], and to inhibit A β cleavage of the amyloid precursor protein APP while assisting in lipid raft formation [50]. Thus, the 2- to 4-fold reduction in *DHCR24* levels that we, for instance, observed in the mouse brain (fig. 2), combined with a several hundred-fold increase in the concentration of desmosterol (even if lasting for only 3–4 weeks in rodents or a few months to a year in humans), might be expected to have nontrivial effects on lipids, membranes and development.

How and when the *DHCR24* promoter came to acquire an active REST binding sequence we cannot say, but its presence must have been either beneficial or indifferent to have been retained in the mammalian genome. The magnitude of the changes in desmosterol and *DHCR24* concentrations in the fetal brain are large and, although of somewhat limited temporal span, with sufficient metabolic effect to suggest the former. Perhaps it was advantageous to have desmosterol acting as an inhibitor keeping sterol biosynthesis [44, 45] in check until parturition when massive quantities of cholesterol are needed very quickly for myelination, or it may be that because desmosterol is a relatively poor substrate for esterification it is better at upregulating the liver X receptor and stimulating astrocyte sterol excretion [8, 51]. So, it is possible that during the sculpting of the young brain enhancing local sterol transport by increasing the supply of free sterol or modulating lipid raft formation by desmosterol and/or *DHCR24* might prove useful. It is also not impossible that desmosterol and *DHCR24*, like 7-dehydrocholesterol and *DHCR7* [52, 53], have additional and as yet undiscovered signaling capabilities, and it may well be that *DHCR24* protein and desmosterol are so essential for brain development that we will find that their concen-

trations are far more closely managed than we had previously thought.

Although we know a good deal about the neuropathology caused by mutated, nonfunctional *DHCR24* [54], one wonders if a mammalian brain in which fetal *DHCR24* protein levels and activity were not suppressed and desmosterol concentrations were more similar to those in the liver or kidney might differ in any material way from a 'normal' brain.

Acknowledgments

This work was supported in part by research grants from the US Department of Veterans Affairs to G.S.T. and from the National Health and the Medical Research Council in Australia (1008081) and National Heart Foundation of Australia (G11S5757) to A.J.B. H.Y. was supported by National Institutes of Health grants HL68660 and HD062938. G.S.T. also wishes to thank Bibiana Pcolinsky for her excellent and dedicated technical support.

References

- Spady DK, Dietschy JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. *J Lipid Res* 1983;24:303–315.
- Chevallier F: Transferts et synthèse du cholestérol chez le rat au cours de sa croissance. *Biochim Biophys Acta* 1964;84:316–339.
- Connor WE, Lin DS: Placental transfer of cholesterol-4- C^{14} into rabbit and guinea pig fetus. *J Lipid Res* 1967;8:558–564.
- Tint GS, Yu H, Shang Q, Xu G, Patel SB: The use of the *Dhcr7* knockout mouse to accurately determine the origin of fetal sterols. *J Lipid Res* 2006;47:1535–1541.
- Hinse CH, Shah SN: The desmosterol reductase activity of rat brain during development. *J Neurochem* 1971;18:1989–1998.
- Kritchevsky D, Holmes WL: Occurrence of desmosterol in developing rat brain. *Biochem Biophys Res Commun* 1962;7:128–131.
- Fumagalli R, Paoletti R: The identification and significance of desmosterol in the developing human and animal brain. *Life Sci* 1963; 5:291–295.
- Jansen M, Wang W, Greco D, Bellenchi GC, di Porzio U, Brown AJ, Ilkonen E: What dictates the accumulation of desmosterol in the developing brain? *FASEB J* 2013;27:865–870.
- Dietschy JM, Turley SD: Cholesterol metabolism in the brain. *Curr Opin Lipidol* 2001;12: 105–112.
- Goodrum JF: Cholesterol synthesis is down-regulated during regeneration of peripheral nerve. *J Neurochem* 1990;54:1709–1715.
- Fitzky BU, Moebius FF, Asaoka H, Waage-Baudet H, Xu L, Xu G, Maeda N, Kluckman K, Hiller S, Yu H, Batta AK, Shefer S, Chen T, Salen G, Sulik K, Simoni RD, Ness GC, Glossmann H, Patel SB, Tint GS: 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. *J Clin Invest* 2001;108:905–915.
- Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, Fitz-Patrick DR, Kelley RI, Wanders RJ: Mutations in the 3β -hydroxysteroid Δ^{24} -reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. *Am J Hum Genet* 2001;69:685–694.
- Bae SH, Paik YK: Cholesterol biosynthesis from lanosterol: development of a novel assay method and characterization of rat liver microsomal lanosterol Δ^{24} -reductase. *Biochem J* 1997;326:609–616.
- Zerenturk EJ, Sharpe LJ, Ilkonen E, Brown AJ: Desmosterol and *DHCR24*: unexpected new directions for a terminal step in cholesterol synthesis. *Prog Lipid Res* 2013;52:666–680.
- Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altschuller YM, Frohman MA, Kraner SD, Mandel G: REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. *Cell* 1995;80:949–957.
- Schoenherr CJ, Anderson DJ: Silencing is golden: negative regulation in the control of neuronal gene transcription. *Curr Opin Neurobiol* 1995;5:566–571.
- Schoenherr CJ, Paquette AJ, Anderson DJ: Identification of potential target genes for the neuron-restrictive silencer factor. *Proc Natl Acad Sci USA* 1996;93:9881–9886.
- Wood IC, Belyaev ND, Bruce AW, Jones C, Mistry M, Roopra A, Buckley NJ: Interaction of the repressor element 1-silencing transcription factor (REST) with target genes. *J Mol Biol* 2003;334:863–874.
- Abramovitz L, Shapira T, Ben Dror I, Dror V, Granot L, Rousso T, Landoy E, Blau L, Thiel G, Vardimon L: Dual role of NRSF/REST in activation and repression of the glucocorticoid response. *J Biol Chem* 2008;283:110–119.
- Bessis A, Champiaux N, Chatelin L, Changeux JP: The neuron-restrictive silencer element: a dual enhancer/silencer crucial for patterned expression of a nicotinic receptor gene in the brain. *Proc Natl Acad Sci USA* 1997;94:5906–5911.
- Kallunki P, Edelman GM, Jones FS: The neural restrictive silencer element can act as both a repressor and enhancer of L1 cell adhesion molecule gene expression during postnatal development. *Proc Natl Acad Sci USA* 1998; 95:3233–3238.
- Seth KA, Majzoub JA: Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. *J Biol Chem* 2001;276:13917–13923.
- Yu H, Wessels A, Chen J, Phelps AL, Oatis J, Tint GS, Patel SB: Late gestational lung hypoplasia in a mouse model of the Smith-Lemli-Opitz syndrome. *BMC Dev Biol* 2004;4:1.
- Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, Chapman M, Gottgens B, Buckley NJ: Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. *Proc Natl Acad Sci USA* 2004;101:10458–10463.
- Zerenturk EJ, Sharpe LJ, Brown AJ: Sterols regulate 3β -hydroxysteroid Δ^{24} -reductase (*DHCR24*) via dual sterol regulatory elements: cooperative induction of key enzymes in lipid synthesis by sterol regulatory element binding proteins. *Biochim Biophys Acta* 2012;1821:1350–1360.
- Tseng WC, Lin JW, Wei TY, Fang TY: A novel megaprimer and ligase-free, PCR-based, site-directed mutagenesis method. *Anal Biochem* 2008;375:376–378.
- Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T: MatInspector and beyond: promoter analysis based on transcription factor binding sites. *Bioinformatics* 2005; 21:2933–2942.
- Drzewinska J, Walczak-Drzewiecka A, Ratajewski M: Identification and analysis of the promoter region of the human *DHCR24* gene: involvement of DNA methylation and histone acetylation. *Mol Biol Rep* 2011;38:1091–1101.
- Daimiel LA, Fernandez-Suarez ME, Rodriguez-Acebes S, Crespo L, Lasuncion MA, Gomez-Coronado D, Martinez-Botas J: Promoter analysis of the *DHCR24* (3β -hydroxysteroid Δ^{24} -reductase) gene: characterization of SREBP (sterol-regulatory-element-binding protein)-mediated activation. *Biosci Rep* 2013;33:57–69.
- Tint GS, Salen G: Evidence for the early reduction of the 24,25 double bond in the conversion of lanosterol to cholesterol in cerebrotendinous xanthomatosis. *Metabolism* 1977; 26:721–729.
- Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G: Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. *N Engl J Med* 1994;330: 107–113.

- 32 Porter FD: Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. *Eur J Hum Genet* 2008;16:535–541.
- 33 Andres ME, Burger C, Peral-Rubio MJ, Battaglioli E, Anderson ME, Grimes J, Dallman J, Ballas N, Mandel G: CoREST: a functional corepressor required for regulation of neural-specific gene expression. *Proc Natl Acad Sci USA* 1999;96:9873–9878.
- 34 Lunyak VV, Burgess R, Prefontaine GG, Nelson C, Sze SH, Chenoweth J, Schwartz P, Pevzner PA, Glass C, Mandel G, Rosenfeld MG: Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. *Science* 2002;298:1747–1752.
- 35 Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhhattar R: A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. *Proc Natl Acad Sci USA* 2002;99:7420–7425.
- 36 Lee MG, Wynder C, Cooch N, Shiekhhattar R: An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. *Nature* 2005;437:432–435.
- 37 Brown MS, Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. *Proc Natl Acad Sci USA* 1999;96:11041–11048.
- 38 Sion B, Grizard G, Boucher D: Quantitative analysis of desmosterol, cholesterol and cholesterol sulfate in semen by high-performance liquid chromatography. *J Chromatogr A* 2001;935:259–265.
- 39 Rinn JL, Rozowsky JS, Laurenzi JJ, Petersen PH, Zou K, Zhong W, Gerstein M, Snyder M: Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. *Dev Cell* 2004;6:791–800.
- 40 Lindenthal B, Holleran AL, Aldaghtas TA, Ruan B, Schroeffer GJ Jr, Wilson WK, Kelleher JK: Progesterone block cholesterol synthesis to produce meiosis-activating sterols. *FASEB J* 2001;15:775–784.
- 41 Clayton PT: Disorders of cholesterol biosynthesis. *Arch Dis Child* 1998;78:185–189.
- 42 Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E, Becker Y, Skalliter R, Einat P, Faerman A, Bjorkhem I, Feinstein E: Generation of viable cholesterol-free mice. *Science* 2003;302:2087.
- 43 Vainio S, Jansen M, Koivusalo M, Rog T, Karttunen M, Vattulainen I, Ikonen E: Significance of sterol structural specificity. Desmosterol cannot replace cholesterol in lipid rafts. *J Biol Chem* 2006;281:348–355.
- 44 Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF, Mangelsdorf DJ, Cohen JC, Hobbs HH: Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. *J Biol Chem* 2006;281:27816–27826.
- 45 Rodriguez-Acebes S, de la CP, Fernandez-Hernando C, Ferruelo AJ, Lasuncion MA, Rawson RB, Martinez-Botas J, Gomez-Coronado D: Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol- Δ^{24} -reductase-deficient cell line. *Biochem J* 2009;420:305–315.
- 46 Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM: The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. *J Neurosci* 2000;20:7345–7352.
- 47 Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puolivali J, Salminen A, Helisalmi S, Soininen H: Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. *Neuroscience* 2002;113:301–310.
- 48 Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K: Regulation of cellular response to oncogenic and oxidative stress by seladin-1. *Nature* 2004;432:640–645.
- 49 Kuehnle K, Crameri A, Kalin RE, Luciani P, Benvenuti S, Peri A, Ratti F, Rodolfo M, Kulic L, Heppner FL, Nitsch RM, Mohajeri MH: Prosurvival effect of DHCR24/seladin-1 in acute and chronic responses to oxidative stress. *Mol Cell Biol* 2008;28:539–550.
- 50 Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH: The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and A β generation in vivo. *EMBO J* 2006;25:432–443.
- 51 Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR: ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. *FASEB J* 2008;22:1073–1082.
- 52 Jiang XS, Wassif CA, Backlund PS, Song L, Holtzclaw LA, Li Z, Yergey AL, Porter FD: Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implications. *Hum Mol Genet* 2010;19:1347–1357.
- 53 Korade Z, Kenworthy AK, Mirnics K: Molecular consequences of altered neuronal cholesterol biosynthesis. *J Neurosci Res* 2009;87:866–875.
- 54 FitzPatrick DR, Keeling JW, Evans MJ, Kan AE, Bell JE, Porteous MEM, Mills K, Winter RM, Clayton PT: Clinical phenotype of desmosterolosis. *Am J Med Genet* 1998;75:145–152.